4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Earnings: $17.1 billion (earnings were $365 million FY23) ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Pharmapack Europe has announced the winners of its newly reformatted Pharmapack Awards, recognizing excellence in six key ...

PacBio, a developer of high-quality, accurate sequencing solutions, has appointed David Ruggiero as the company’s new Global ...

New kits are designed to offer a convenient method to label any antibody with one of Bio-Rad’s StarBright Dyes.

Trilobio, developer of whole lab automation systems for biology research, introduced the first version of its comprehensive robotics, lab equipment and software platform.

Recipharm’s new modular sterile filling system, specifically tailored for process development, pilot scale and clinical ...

Independent research institute BioMed X has completed its oncology research project in partnership with Merck, the data from ...

The Chan Zuckerberg Initiative (CZI), in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading ...

In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings was completed.

4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...